Sun Pharma shares rose 0.65 per cent to close at Rs 1,798.80. At this level, the stock has climbed 4.56 per cent year-to-date (YTD).
Organon completes agreement to license MIUDELLA®, Sebela’s hormone-free IUD, expanding its long-acting reversible contraception portfolio ...
Five years after launching as a global healthcare company committed to delivering impactful medicines and solutions for a healthier every day, Organon is ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the completion of a global licensing agreement ...
TheFly reported on June 22 that OGN announced the completion of a global licensing agreement with Sebela Pharmaceuticals, ...
Sun Pharma expects strong cash flows from the combined business to support debt reduction, innovation investments and growth across specialty medicines, women’s health and global markets.
The launch expands Organon’s biosimilars portfolio in Canada to eight products spanning five therapeutic areas.
Zacks Investment Research on MSN
Organon & Co. (OGN) is attracting investor attention: Here is what you should know
Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...
Organon Canada and Shanghai Henlius Biotech, Inc. (2696.HK) today announced that BILDYOS ® (denosumab injection) 60 mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results